



FOR IMMEDIATE RELEASE

Contact: Sharon Schultz
Tel: (301) 351-0109
email: schultzpr@mchsi.com

ADOPTION OF ISORAY'S CESIUM-131 TREATMENT FOR LUNG CANCER GAINS MOMENTUM USING DA VINCI ROBOTICS SYSTEM

*IsoRay's Innovative Internal Radiation Therapy and da Vinci Robotics
Reduces Cancer Reoccurrence in Early Stage Lung Cancer Treatment*

Richland, WA (August 22, 2011) - - **IsoRay, Inc. (Amex: ISR)** said today that a growing number of hospitals and medical treatment centers are adopting its proprietary mesh **Cesium-131 (Cs-131) brachytherapy seeds** (internal radiation therapy) for use in conjunction with the da Vinci[®] Surgical System to treat early stage lung cancer patients. One of the most recent adopters is Georgia's Archbold Memorial Hospital.

In recently published comments, **Archbold Memorial Hospital announced it has become the first in the state of Georgia, "to revolutionize surgical treatment for lung cancer using mesh brachytherapy and the da Vinci Robot."** General and thoracic surgeon Edward Hall, MD, and radiation oncologist Steven Johnson, MD, of Archbold's Lewis Hall Singletary Oncology Center performed the surgery on a 64-year old female patient. To hear more about the doctors' experience and what the patient has to say, follow this link. <http://www.walb.com/story/15238595/new-procedure-may>

According to radiation oncologist Johnson, **"With mesh brachytherapy, patients benefit from getting the most targeted radiation possible, which decreases the chance of the cancer recurring and decreases the amount of potential lung damage...placing Cesium (131), a radioactive chemical element used for treating cancer, over the suture line reduces the risk of cancer recurrence in patients to 10 percent or less,"** said Johnson.

IsoRay's Cesium-131 mesh brachytherapy gives physicians and their patients a viable treatment option for those cancer patients who otherwise would be inoperable because of limited pulmonary function or other health issues. Patients accrue additional benefits because targeted radiation does not involve the many weeks of treatment required in traditional external radiation since it can be done at the time of surgery and does not involve return trips to the hospital, except for routine follow-up visits. **Cesium-131 brachytherapy treatments are demonstrating their efficacy in cancer control and survivability as well as in their positive impact on quality of life for patients.**

IsoRay CEO Dwight Babcock says the combination of da Vinci robotics and his company's Cesium-131 mesh brachytherapy is proving a winning combination,"We are hearing from a number of physicians and medical facilities, who are looking at applications to treat a variety of cancers throughout the body. We are confident that this interest and excitement will translate into important benefits for patients who are fighting the toughest battles of their lives. This is about cancer control and survival and it comes with improved quality of life. I continue to believe that it's the insurance policy no patient can afford to be without. "

IsoRay is the exclusive manufacturer of Cesium-131. **The pioneering brachytherapy treatment represents one of the most important advancements in internal radiation therapy in 20 years.** In addition to its CMS codes, Cesium-131 is FDA-cleared for the treatment of **prostate, lung, ocular melanoma, brain, colorectal, gynecological, and head and neck cancer** and other cancers throughout the body.

###

About IsoRay, Inc.

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com.

Safe Harbor Statement

Statements in this news release about IsoRay's future expectations, including: the advantages of our Cesium-131 seed, the advantages of Cesium-131, the mesh brachytherapy application and the da Vinci[®] surgery system in lung cancer applications, whether IsoRay's Cesium-131 seed will be used to treat additional cancers and malignant disease, whether the use of Cesium-131 to treat lung cancers will be successful both long- and short-term in the initial and any future implants, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of early clinical studies, whether implants of Cesium-131 to treat lung cancers result in favorable patient outcomes, patient results achieved when Cesium-131 is used for the treatment of cancers and malignant diseases beyond prostate cancer, whether hospitals, medical treatment centers and physicians continue to adopt Cs-131 mesh brachytherapy used in conjunction with the da Vinci[®] surgical system to treat early stage lung cancers, successful completion of future research and development activities, and other risks detailed from time to time in IsoRay's reports filed with the SEC.